MDA-assisted psychotherapy with neurotic outpatients: a pilot study

Area of Science:

• Psychiatry
• Clinical Psychology
• Pharmacology

Background:

• Neurotic disorders present complex challenges for traditional psychotherapy.
• Adjunctive pharmacological interventions are explored to enhance psychotherapeutic efficacy.

Purpose of the Study:

• To investigate the efficacy of psychotherapy augmented with 3,4-methylenedioxyamphetamine (MDA) in treating neurotic patients.
• To assess the safety and tolerability of MDA as an adjunct in psychotherapy.

Main Methods:

• Ten neurotic outpatients received psychotherapy (mean 51.55 hours) over 2-6 months.
• 2-4 sessions of MDA (75-200 mg) were administered after establishing therapeutic rapport.
• Psychometric assessments (MMPI, WPRS, BPRS, SHQ) were used pre- and post-treatment and at 6-month follow-up.

Main Results:

• MDA was well-tolerated with no serious adverse events observed.
• Significant reductions in depression, anxiety, and obsessive-compulsive traits were noted.
• Measures of well-being and self-actualization showed encouraging improvements.

Conclusions:

• Psychotherapy combined with adjunctive MDA appears to facilitate clinical improvement in neurotic patients.
• The treatment approach was associated with positive psychometric changes and was generally well-tolerated.
• Further research is warranted to explore the therapeutic potential of MDA in psychiatric treatment.